Alar Pharmaceuticals Inc. (TPEX:6785)

Market Cap	20.31B
Revenue (ttm)	1.25M
Net Income (ttm)	-29.36M
Shares Out	66.80M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	0.25 (0.08%)
Ex-Dividend Date	Jun 10, 2025

Volume	134,925
Average Volume	238,654
Open	302.00
Previous Close	298.50
Day's Range	300.50 - 308.00
52-Week Range	108.50 - 317.00
Beta	0.31
RSI	63.87
Earnings Date	Mar 13, 2026

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 27
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6785

Financial Performance

In 2024, Alar Pharmaceuticals's revenue was 5.82 million, a decrease of -98.76% compared to the previous year's 469.27 million. Earnings were 18.17 million, a decrease of -95.25%.